Behrad Derakhshan - Feb 5, 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Business Officer
Signature
/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan
Stock symbol
EWTX
Transactions as of
Feb 5, 2025
Transactions value $
-$281,000
Form type
4
Date filed
2/7/2025, 04:37 PM
Previous filing
Sep 24, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $19.3K +10K +59.39% $1.93 26.8K Feb 5, 2025 Direct F1
transaction EWTX Common Stock Sale -$300K -10K -37.26% $30.03 16.8K Feb 5, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -10K -9.72% $0.00 92.9K Feb 5, 2025 Common Stock 10K $1.93 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,716 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.